Not yet taking people in ChinaNo phase
Studies ustekinumab treatment for anal fistulas in Crohn's disease patients
Looks at how well individualized ustekinumab treatment works in adults with Crohn's anal fistulas.
Key facts
- Who runs it
- Second Affiliated Hospital of Wenzhou Medical University
- Where
- Wenzhou, ChinaSee the site
- Trial code
- Registry title
- Individual Treatment of Ustekinumab in Perianal Fistulizing Crohn's Disease
- Status
- Not yet recruiting
- People taking part
- 119 people, planned
- Started
- 20 Dec 2024
- Planned end
- 31 Jan 2025
- Type of study
- Observational
- Record updated
- 18 December 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Crohn's disease who have fistulas around the anus and are treated with ustekinumab.
- Age
- 18 Years to 65 Years
- Sex
- All sexes can join.
- Disease stage
- Clinical diagnosis of perianal fistulizing Crohn's disease.
- Earlier treatment
- Must receive ustekinumab therapy. Ustekinumab combined with hormones, immunosuppressants, other biologics or small molecule drugs is an exclusion.
Main reasons for not taking part
- Ustekinumab combined with hormones, immunosuppressants, other biologics or small molecule drugs
- Other autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Graves disease
- Serious infectious diseases, such as active tuberculosis, EBV infection, cytomegalovirus infection
- Malignant tumor
- Clinical data missing ≥30% or no follow-up
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Clinical diagnosis of Perianal Fistulizing Crohn's Disease
- Receive ustekinumab therapy
Who cannot take part
- Ustekinumab combined with hormones, immunosuppressants, other biologics or small molecule drugs
- Combined with other autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Graves disease, etc
- Combined with serious infectious diseases, such as active tuberculosis, EBV infection, cytomegalovirus infection, etc
- Combined with malignant tumor
- Clinical data missing ≥30% or no follow-up
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in China
- The Second Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaContact: Luyan FangNo longer taking part
About the trial
What the trial wants to find out
This study intends to further explore the actual efficacy of ustekinumab in the individualized treatment of anal fistula Crohn's disease.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Analysis for the Efficacy of Individual Treatment of Perianal Fistulizing Crohn's Disease With Ustekinumab
- Plain-language title
- Studies ustekinumab treatment for anal fistulas in Crohn's disease patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06739278, who can take part
- Record updated
- 18 December 2024